Antion Biosciences to Present at Upcoming Scientific Conferences

Antion Biosciences to Present at Upcoming Scientific Conferences

• Abstract acceptance at the American Society of Gene & Cell Therapy (ASGCT) Virtual Annual Meeting and the International Society of Cell & Gene Therapy (ISCT) Virtual Annual Meeting

Geneva, Switzerland, 13 April 2021 - Antion Biosciences (‘Antion’ or ‘the Company’), a Swiss cell and gene engineering company developing highly innovative allogeneic therapies to cure diseases with significant unmet medical need, is pleased to announce that it will be presenting two posters at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place 11-14 May, and presenting two posters at the International Society of Cell & Gene Therapy (ISCT) Virtual Annual Meeting taking place 26-28 May 2021.

The abstract titles for ASGCT are below:

1. A novel bimodal gene construct for multiplex cell engineering and the development of allogeneic chimeric antigen receptor T-cells
2. Development of anti-CD19 chimeric antigen receptor T-cells with immune checkpoint silencing

Registered attendees can view the full abstracts on the ASGCT website from Tuesday 27 April. The digital presentations will be available for registered attendees on the ASGCT website on Tuesday 11 May: https://annualmeeting.asgct.org/

The abstract titles for ISCT are below:

1. Multiplex gene silencing as a promising tool for development of next generation immune effector cell therapies
2. Development of an off-the-shelf CAR T-cell therapy for HIV:  A step towards a universally accessible advanced therapy

Registered attendees can view the posters in the poster hall during the event. More information can be found on the ISCT website here: https://isct2021.com/